Search

Your search keyword '"Go, Ronald"' showing total 2,514 results

Search Constraints

Start Over You searched for: Author "Go, Ronald" Remove constraint Author: "Go, Ronald"
2,514 results on '"Go, Ronald"'

Search Results

1. Capillary leak phenotype as a major cause of death in patients with POEMS syndrome: MULTIPLE MYELOMA, GAMMOPATHIES

2. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events

3. Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms

4. Clinical features and outcomes in primary nervous system histiocytic neoplasms

5. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

6. Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020

7. Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era

8. Venous and arterial thrombosis in patients with VEXAS syndrome

9. A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura

10. Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation

12. Neurological Manifestations of Histiocytic Disorders

14. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

15. Long-term outcomes among adults with Langerhans cell histiocytosis

18. Spectrum of clonal hematopoiesis in VEXAS syndrome

19. Pulmonary manifestations in VEXAS syndrome

21. Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes

23. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis

24. Race, rituximab, and relapse in TTP

25. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

26. SLC29A3 Pathogenic Variants Resulting in Dural Based Fibroinflammatory Mass Lesions and H Syndrome Treated With Cobimetinib: A Case Report.

27. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

31. Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy

32. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma

33. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center

34. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update

35. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy

36. Prognostic restaging after treatment initiation in patients with AL amyloidosis

37. Coagulation Abnormalities in Light Chain Amyloidosis

38. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

39. Female Representation in Clinical Practice Guideline Panels in 2 Major Cancer Organizations

40. Personalized Medicine in Histiocytic Disorders: Novel Targets in Patients Without MAPK Alterations.

45. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

46. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

47. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma

50. C3+ and C3− warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes

Catalog

Books, media, physical & digital resources